Pharma supply chains

Swiss medtech fears major blow over US tariffs

Already overtaxed in the USA, Swiss medtech fears a major blow

This content was published on Oct 15, 2025 The Swiss medtech sector faces steep US tariffs and new trade hurdles.

Two white drug tablets on a red background.

Drug pricing

Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval

This content was published on Oct 8, 2025 Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.

Government circles: New US pharmaceutical tariffs to start later

Global trade

US delays pharma tariffs to push for more drug pricing deals

This content was published on Oct 2, 2025 US delays pharma tariffs, urging companies to relocate production or lower prices.

Talks between pharma and government stall

Pharma supply chains

Talks between pharma and Swiss government stall

This content was published on Sep 23, 2025 Discussions between pharma and the Federal Council on Monday evening failed to produce a clear solution to the US customs policy. Economy Minister Guy Parmelin spoke of "constructive" discussions, but did not offer any concrete suggestions.

Healthcare innovation

How Novartis got ahead on ‘incredible’ cancer breakthrough

This content was published on Sep 2, 2025 The Swiss pharma group has become a pioneer in a new type of targeted radiotherapy.

Pharma supply chains

Swiss medtech industry shows strong support for EU deal

This content was published on Aug 30, 2025 Over 70% of Swiss medtech firms back the EU deal, citing market access and free movement.

Pharma supply chains

Ypsomed CEO: US production to begin in 2027

This content was published on Aug 30, 2025 Ypsomed CEO explains why US tariffs are not a worry and why he sees more growth from diabetes and obesity treatments such as Ozempic.

Drug pricing

How pharma became Switzerland’s Achilles heel in US trade talks

This content was published on Aug 6, 2025 The pharmaceutical industry’s strength has made it a key vulnerability for Switzerland in trade talks with the US.

Roche CEO: 'Agreement between Bern and Washington within days, if not hours'

Drug pricing

Switzerland very close to tariff deal with the US, says Roche CEO

This content was published on Jul 25, 2025 An understanding between Berne and Washington in the dispute over customs barriers is close: Roche CEO Thomas Schinecker is convinced of this.

Drug pricing

Roche boss says ‘very easy’ to cut US drug prices by 50%

This content was published on Jul 24, 2025 Swiss pharma group Roche is in talks with Washington to bypass middlemen and sell directly to consumers.

Pharma supply chains

Popular Stories

Most Discussed

Sign in and personalize Swissinfo

Pharma supply chains

More

Swiss medtech fears major blow over US tariffs

More

Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval

More

US delays pharma tariffs to push for more drug pricing deals

More

Talks between pharma and Swiss government stall

More

How Novartis got ahead on ‘incredible’ cancer breakthrough

More

Swiss medtech industry shows strong support for EU deal

More

Ypsomed CEO: US production to begin in 2027

More

How pharma became Switzerland’s Achilles heel in US trade talks

More

Switzerland very close to tariff deal with the US, says Roche CEO

More

Roche boss says ‘very easy’ to cut US drug prices by 50%

Popular Stories

Most Discussed